See more : Di Dong Il Corporation (001530.KS) Income Statement Analysis – Financial Results
Complete financial analysis of Veru Inc. (VERU) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Veru Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Talenthouse AG (NEWN.SW) Income Statement Analysis – Financial Results
- DP Aircraft I Limited (DPA.L) Income Statement Analysis – Financial Results
- Qatar Navigation Q.P.S.C. (QNNS.QA) Income Statement Analysis – Financial Results
- Maj Invest Grønne Obligationer (MAJGRO.CO) Income Statement Analysis – Financial Results
- PT Perusahaan Gas Negara Tbk (PGAS.JK) Income Statement Analysis – Financial Results
Veru Inc. (VERU)
About Veru Inc.
Veru Inc., an oncology biopharmaceutical company, focuses on developing medicines for the management of cancers. Its commercial products comprise FC2 female condom/internal condom for the dual protection against unintended pregnancy and the transmission of sexually transmitted infections for ministries of health, government health agencies, U.N. agencies, nonprofit organizations, and commercial partners. The company's development drug candidates include Enobosarm, an oral selective androgen receptor agonist that is in phase III clinical trial for the treatment of AR+ ER+ HER2- metastatic breast cancer; Sabizabulin, which is phase IIb clinical trial for the treatment of AR+ ER+ HER2- metastatic breast cancer; Enobosarm + abemaciclib combination therapy, which is in phase III clinical trial for the treatment of AR+ ER+ HER2- metastatic breast cancer; and Sabizabulin + enobosarm combination therapy, an oral targeted cytoskeleton disruptor plus selective androgen receptor agonist, which is in phase II clinical trial for the treatment of metastatic triple negative breast cancer. Its drug candidates also comprise Sabizabulin, which is in Phase II clinical trial for the treatment of metastatic castration and androgen receptor targeting agent resistant prostate cancer; VERU-100, a GnRH antagonist peptide injection, which is in Phase II clinical trial for the treatment of advanced hormone sensitive prostate cancer; Zuclomiphene Citrate, which is in Phase II clinical trial for treating hot flashes; and Sabizabulin, which is in phase III clinical trial for the treatment of SARS-CoV-2 in subjects at high risk for acute respiratory distress syndrome. In addition, the company is advancing a new drug formulation for the treatment of men with lower urinary tract symptoms from an enlarged prostate. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. was incorporated in 1971 and is headquartered in Miami, Florida.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 | 1992 | 1991 | 1990 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 16.89M | 16.30M | 39.35M | 61.26M | 42.59M | 31.80M | 15.86M | 13.66M | 22.13M | 32.60M | 24.49M | 31.46M | 35.03M | 18.57M | 22.22M | 27.54M | 25.63M | 19.32M | 14.82M | 11.16M | 8.83M | 9.05M | 8.42M | 6.72M | 5.77M | 4.72M | 5.45M | 2.92M | 2.06M | 2.20M | 16.20M | 12.50M | 11.20M | 13.10M | 10.70M |
| Cost of Revenue | 11.03M | 8.73M | 8.76M | 13.33M | 11.81M | 10.15M | 7.08M | 6.64M | 8.78M | 13.63M | 11.37M | 13.95M | 14.41M | 8.70M | 9.30M | 14.03M | 14.90M | 12.16M | 9.33M | 6.37M | 5.21M | 5.46M | 4.86M | 5.34M | 3.60M | 3.31M | 5.27M | 3.48M | 3.68M | 2.50M | 7.50M | 6.90M | 6.10M | 7.20M | 6.10M |
| Gross Profit | 5.85M | 7.57M | 30.59M | 47.93M | 30.79M | 21.66M | 8.78M | 7.02M | 13.35M | 18.97M | 13.12M | 17.50M | 20.62M | 9.87M | 12.92M | 13.52M | 10.73M | 7.16M | 5.49M | 4.79M | 3.62M | 3.59M | 3.56M | 1.38M | 2.16M | 1.40M | 178.03K | -559.30K | -1.62M | -300.00K | 8.70M | 5.60M | 5.10M | 5.90M | 4.60M |
| Gross Profit Ratio | 34.67% | 46.43% | 77.73% | 78.24% | 72.28% | 68.10% | 55.36% | 51.40% | 60.33% | 58.18% | 53.58% | 55.65% | 58.86% | 53.14% | 58.16% | 49.08% | 41.86% | 37.04% | 37.03% | 42.93% | 41.03% | 39.67% | 42.31% | 20.52% | 37.49% | 29.70% | 3.27% | -19.18% | -78.50% | -13.64% | 53.70% | 44.80% | 45.54% | 45.04% | 42.99% |
| Research & Development | 12.81M | 51.20M | 70.65M | 32.69M | 16.94M | 13.74M | 10.85M | 3.50M | 99.39K | 219.82K | 5.58K | 4.75K | 5.28K | 10.93K | 381.00 | 105.92K | 284.22K | 208.61K | 210.88K | 273.78K | 179.20K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 361.09K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 31.18M | 48.06M | 43.17M | 20.67M | 14.50M | 14.35M | 14.82M | 11.02M | 8.66M | 12.13M | 9.14M | 7.49M | 9.63M | 6.23M | 6.43M | 7.01M | 7.04M | 5.89M | 4.82M | 5.71M | 4.46M | 4.89M | 4.93M | 1.85M | 2.97M | 3.14M | 2.90M | 3.04M | 2.99M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 54.27K | 88.87K | 0.00 | 58.12K | 221.72K | 52.95K | 332.76K | 220.18K | 191.15K | 223.80K | 179.87K | 218.50K | 123.10K | 47.60K | 36.53K | 43.83K | 129.16K | 0.00 | 0.00 | 433.82K | 1.64M | 2.98M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 31.18M | 48.06M | 43.17M | 20.67M | 14.50M | 14.35M | 14.82M | 11.07M | 8.75M | 12.13M | 9.20M | 7.71M | 9.68M | 6.56M | 6.65M | 7.20M | 7.26M | 6.07M | 5.04M | 5.83M | 4.51M | 4.92M | 4.97M | 1.98M | 2.97M | 3.14M | 3.33M | 4.68M | 5.97M | 8.00M | 10.70M | 8.10M | 6.20M | 7.10M | 3.70M |
| Other Expenses | -1.22M | 2.09M | -316.06K | -8.71M | 14.10M | -5.89M | -2.20M | 15.51M | 9.20M | 9.20M | 9.20M | 7.71M | 2.01M | 1.69M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.26M | 0.00 | 1.83M | 1.28M | 0.00 | 0.00 | 0.00 | 100.00K | 500.00K | 400.00K | 300.00K | 200.00K | 100.00K |
| Operating Expenses | 42.77M | 101.35M | 113.81M | 53.36M | 45.53M | 28.09M | 29.65M | 14.58M | 10.33M | 12.35M | 9.20M | 7.71M | 9.68M | 6.57M | 6.65M | 7.30M | 7.55M | 6.28M | 5.25M | 6.10M | 4.69M | 4.92M | 6.23M | 1.98M | 4.80M | 4.43M | 3.33M | 4.68M | 6.33M | 8.10M | 11.20M | 8.50M | 6.50M | 7.30M | 3.80M |
| Cost & Expenses | 53.80M | 110.08M | 122.58M | 66.70M | 57.34M | 38.24M | 36.74M | 21.21M | 19.11M | 25.99M | 20.57M | 21.67M | 24.09M | 15.27M | 15.94M | 21.33M | 22.45M | 18.44M | 14.58M | 12.47M | 9.90M | 10.38M | 11.09M | 7.32M | 8.41M | 7.74M | 8.60M | 8.15M | 10.01M | 10.60M | 18.70M | 15.40M | 12.60M | 14.50M | 9.90M |
| Interest Income | 0.00 | 0.00 | 4.37M | 4.89M | 4.62M | 4.71M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 29.17K | 55.98K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 607.47K | 2.43M | 4.37M | 4.85M | 4.62M | 4.71M | 2.95M | 2.04M | 3.32M | 0.00 | 50.57K | 0.00 | 296.18K | 124.63K | 3.98M | 2.39M | 0.00 | 74.91K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 268.18K | 269.87K | 209.60K | 593.87K | 783.64K | 471.42K | 452.05K | 481.01K | 422.87K | 494.26K | 589.34K | 556.30K | 461.45K | 464.91K | 466.54K | 268.38K | 217.09K | 252.94K | 333.63K | 522.80K | 1.09M | 1.55M | 1.01M | 923.92K | 1.83M | 1.28M | 533.99K | 553.30K | 675.08K | -100.00K | -500.00K | -400.00K | -300.00K | -200.00K | -100.00K |
| EBITDA | -36.20M | -89.98M | -79.23M | 9.75M | -14.65M | -7.14M | -19.67M | -8.12M | 4.92M | 7.11M | 4.51M | 10.35M | 11.40M | 3.76M | 4.69M | 5.32M | 3.40M | 1.01M | 573.99K | -1.11M | 19.17K | 210.53K | -1.66M | 321.06K | -812.89K | -1.74M | -2.73M | -4.76M | -7.10M | -8.30M | -2.20M | -2.50M | -1.10M | -1.60M | 800.00K |
| EBITDA Ratio | -214.38% | -552.10% | -211.47% | -38.93% | -34.62% | -20.24% | -131.57% | -44.52% | 16.22% | 21.64% | 18.77% | 33.21% | 31.65% | 18.08% | 39.04% | 26.99% | 9.08% | 6.19% | 3.96% | -6.94% | 0.94% | 2.33% | -4.75% | 2.98% | -16.61% | -39.07% | -50.15% | -163.37% | -340.18% | -377.27% | -13.58% | -20.00% | 8.93% | -12.21% | 7.48% |
| Operating Income | -36.92M | -93.78M | -83.22M | -5.44M | -14.75M | -6.44M | -20.87M | -8.49M | 3.02M | 6.62M | 3.92M | 9.79M | 10.94M | 3.30M | 4.35M | 4.72M | 3.18M | 875.91K | 240.36K | -1.31M | -1.07M | -1.34M | -2.67M | -602.86K | -2.64M | -3.03M | -3.15M | -5.24M | -7.95M | -8.20M | -1.70M | -2.10M | 1.30M | -1.40M | 900.00K |
| Operating Income Ratio | -218.61% | -575.46% | -211.47% | -8.88% | -34.62% | -20.24% | -131.57% | -62.20% | 13.64% | 20.30% | 16.02% | 31.12% | 31.23% | 17.75% | 19.57% | 17.13% | 12.42% | 4.53% | 1.62% | -11.75% | -12.09% | -14.76% | -31.72% | -8.98% | -45.75% | -64.17% | -57.80% | -179.62% | -385.12% | -372.73% | -10.49% | -16.80% | 11.61% | -10.69% | 8.41% |
| Total Other Income/Expenses | -160.93K | 1.11M | -316.06K | -8.71M | -5.31M | -5.89M | -2.20M | -108.38K | -204.60K | 68.63K | 33.28K | 144.26K | -147.91K | -63.37K | -125.03K | 332.10K | 1.02M | -7.00K | -12.35K | -44.40K | 0.00 | 0.00 | -1.26M | -568.40K | 145.20K | 100.18K | 117.14K | 79.53K | -252.61K | 0.00 | 1.00M | 0.00 | 600.00K | 400.00K | 200.00K |
| Income Before Tax | -37.08M | -92.67M | -83.54M | 4.27M | -20.05M | -12.32M | -23.07M | -8.60M | 2.81M | 6.69M | 3.96M | 9.93M | 10.79M | 3.23M | 4.22M | 5.05M | 4.20M | 868.91K | 228.01K | -1.33M | -1.07M | 0.00 | -3.93M | -1.17M | -2.49M | -2.93M | -3.03M | -5.16M | -8.20M | 0.00 | -1.50M | 0.00 | -800.00K | -1.00M | 1.00M |
| Income Before Tax Ratio | -219.56% | -568.65% | -212.28% | 6.96% | -47.08% | -38.74% | -145.43% | -63.00% | 12.72% | 20.51% | 16.16% | 31.58% | 30.80% | 17.41% | 19.01% | 18.34% | 16.40% | 4.50% | 1.54% | -11.87% | -12.09% | 0.00% | -46.67% | -17.44% | -43.23% | -62.05% | -55.65% | -176.89% | -397.36% | 0.00% | -9.26% | 0.00% | -7.14% | -7.63% | 9.35% |
| Income Tax Expense | 725.10K | 480.21K | 236.40K | -3.13M | -1.08M | -303.93K | 866.10K | -1.99M | 2.47M | 2.34M | 1.52M | -4.41M | -4.51M | -2.17M | -2.51M | -1.49M | -762.86K | -825.00K | -29.32K | 58.51K | 1.02M | 1.04M | 2.07M | 447.43K | 906.65K | 624.13K | 89.28K | 291.21K | 963.00K | 100.00K | 1.30M | 1.60M | 5.60M | 100.00K | 600.00K |
| Net Income | -37.80M | -93.15M | -83.78M | 7.39M | -18.97M | -12.02M | -23.94M | -6.61M | 344.73K | 4.35M | 2.43M | 14.34M | 15.30M | 5.40M | 6.74M | 6.54M | 4.97M | 1.69M | 282.03K | -1.36M | -2.02M | -2.37M | -3.48M | -1.17M | -3.69M | -3.75M | -3.36M | -5.61M | -8.66M | -8.30M | -3.00M | -3.70M | -4.30M | -1.50M | 300.00K |
| Net Income Ratio | -223.86% | -571.60% | -212.88% | 12.07% | -44.55% | -37.79% | -150.89% | -48.42% | 1.56% | 13.33% | 9.93% | 45.59% | 43.67% | 29.08% | 30.32% | 23.73% | 19.38% | 8.77% | 1.90% | -12.15% | -22.87% | -26.20% | -41.36% | -17.44% | -63.99% | -79.53% | -61.59% | -192.33% | -419.54% | -377.27% | -18.52% | -29.60% | -38.39% | -11.45% | 2.80% |
| EPS | -0.28 | -1.10 | -1.05 | 0.10 | -0.28 | -0.19 | -0.44 | -0.19 | 0.01 | 0.15 | 0.09 | 0.51 | 0.55 | 0.20 | 0.25 | 0.25 | 0.18 | 0.06 | 0.01 | -0.06 | -0.10 | -0.12 | -0.21 | -0.08 | -0.29 | -0.34 | -0.34 | -0.66 | -1.30 | -1.39 | -0.62 | -0.96 | -1.24 | -0.45 | 0.14 |
| EPS Diluted | -0.28 | -1.10 | -1.05 | 0.09 | -0.28 | -0.19 | -0.44 | -0.19 | 0.01 | 0.15 | 0.08 | 0.50 | 0.53 | 0.19 | 0.24 | 0.24 | 0.18 | 0.06 | 0.01 | -0.06 | -0.10 | -0.12 | -0.21 | -0.08 | -0.29 | -0.34 | -0.34 | -0.66 | -1.30 | -1.39 | -0.62 | -0.96 | -1.24 | -0.45 | 0.14 |
| Weighted Avg Shares Out | 134.88M | 84.97M | 80.12M | 76.27M | 66.75M | 63.32M | 53.86M | 34.41M | 28.67M | 28.53M | 28.52M | 28.38M | 27.69M | 27.29M | 26.98M | 25.65M | 26.12M | 24.95M | 23.80M | 21.67M | 19.33M | 19.02M | 16.24M | 14.63M | 12.76M | 10.89M | 10.00M | 8.51M | 6.64M | 5.97M | 4.84M | 3.85M | 3.47M | 3.33M | 3.28M |
| Weighted Avg Shares Out (Dil) | 134.88M | 84.97M | 80.12M | 83.80M | 66.75M | 63.32M | 53.86M | 34.64M | 28.93M | 28.92M | 28.87M | 28.73M | 28.93M | 28.97M | 28.55M | 27.81M | 27.98M | 26.40M | 26.49M | 21.67M | 19.33M | 19.02M | 16.24M | 14.63M | 12.76M | 10.89M | 10.00M | 8.51M | 6.64M | 5.97M | 4.84M | 3.85M | 3.47M | 3.33M | 3.28M |
Veru to Present at the 17th International Conference of the Society on Sarcopenia, Cachexia, & Wasting Disorders
MIAMI, FL, Nov. 26, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight loss, oncology, and viral induced acute respiratory distress syndrome, today...
Veru Announces Meta-analysis of Body Composition Data from Older Patients with Obesity which Supports Potential for Enobosarm to Optimize Weight Loss at ObesityWeek
MIAMI, FL, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight loss, oncology, and viral induced acute respiratory distress syndrome, today...
Veru to Present at ObesityWeek: Meta-Analysis of 4 Previous Randomized Clinical Trials that Support the Potential of Enobosarm to Optimize Weight Loss
MIAMI, FL, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight loss, oncology, and viral induced acute respiratory distress syndrome, today...
Veru to Deliver Keynote Presentation on the Scientific Support for Enobosarm in Combination with GLP-1 Receptor Agonist to Preserve Muscle for Higher Quality Weight Loss at the 4th Edition of the World Obesity and Weight Management Congress
MIAMI, FL, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight loss, oncology, and viral induced acute respiratory distress syndrome, today...
Veru to Present at the 2024 Cantor Global Healthcare Conference
MIAMI, FL, Sept. 11, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight loss, oncology, and viral induced acute respiratory distress syndrome, today...
Veru Inc. (VERU) Q3 2024 Earnings Call Transcript
Veru Inc. (NASDAQ:VERU ) Q3 2024 Results Conference Call August 8, 2024 8:00 AM ET Company Participants Sam Fisch - Investor Relations & Corporate Communications Mitchell Steiner - Chief Executive Officer Michele Greco - Chief Financial Officer Gary Barnette -...
Veru Inc. (VERU) Reports Q3 Loss, Tops Revenue Estimates
Veru Inc. (VERU) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of a loss of $0.06. This compares to loss of $0.13 per share a year ago.
Veru Reaches Full Enrollment for Phase 2b QUALITY Clinical Study of Enobosarm for Obesity and Reports Fiscal 2024 Third Quarter Financial Results
--Phase 2b QUALITY study of enobosarm in combination with semaglutide (Wegovy®*) exceeds targeted full enrollment of >150 patients-- --Topline data for primary endpoint of lean body mass expected January 2025--
Veru to Report Fiscal 2024 Third Quarter Financial Results on August 8, 2024
MIAMI, FL, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight loss, oncology, and viral induced acute respiratory distress syndrome, today...
Veru to Participate in the BTIG Virtual Biotechnology Conference
MIAMI, FL, July 29, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight loss, oncology, and viral induced acute respiratory distress syndrome, today...
Source: https://incomestatements.info
Category: Stock Reports